Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Allos Therapeutics —The company has a positive last trial for treating T-cell lymphoma, bladder cancer and lung cancer. “People may be treated in the real world by the end of this year,” Monane told CNBC.
Medarex —The company is in its late stage programs in testing melanoma, a tough-to-treat cancer. They also have solid partnerships with Bristol-Myers, Merck and Johnson & Johnson.
Vertex Pharmaceuticals —They are in their last phase in developing a treatment for Hepatitis C.
No immediate information was available for Monane or his firm.